S-1: Tivic Health Systems Eyes $25 Million Capital Injection via Stock Resale Program

Tivic Health Systems is registering for the resale of up to 292,523 shares of its common stock by Mast Hill Fund, potentially generating up to $25 million for the company through a purchase agreement.

Summary

• Tivic Health Systems has filed a registration statement for the potential resale of up to 292,523 shares of its common stock.
• The shares are to be resold by Mast Hill Fund, L.P., a selling stockholder, and consist of commitment shares and shares that may be purchased under an equity purchase agreement.
• Tivic Health could receive up to $25 million from the sale of shares to Mast Hill under the purchase agreement, once the registration statement is effective.
• The company will not receive any proceeds from the resale of shares by Mast Hill.
• The purpose of the registration is to satisfy certain registration rights granted to Mast Hill.
• Tivic Health is an emerging growth company and a smaller reporting company, allowing it to comply with reduced reporting requirements.
• The company's common stock is traded on the Nasdaq Capital Market under the symbol TIVC.
• The last reported sale price of Tivic Health's common stock on May 7, 2025, was $4.30 per share.
• The company implemented a 1-for-17 reverse stock split on March 7, 2025, and a 1-for-100 reverse stock split on August 23, 2023.

Sentiment

Score: 5

Explanation: The document presents a neutral outlook. While the potential capital injection is positive, the dilution risk and market uncertainties temper the overall sentiment.

Positives

• The potential for Tivic Health to receive up to $25 million in funding from the sale of shares to Mast Hill.
• The company has an FDA-approved over-the-counter device, ClearUP, for treating sinus pain, pressure, and congestion.
• Tivic Health has acquired rights to Entolimod, a late-stage TLR5 agonist, for the treatment of acute radiation syndrome, which has Fast Track and Orphan Drug designation from the FDA.
• The company is preparing to file an IND application and initiate a phase 2 clinical study for Entolimod for the treatment of neutropenia.
• The company has completed an initial clinical validation study with the Feinstein Institute for the Bioelectronic Medicine at Northwell Health (Feinstein) with encouraging results.

Negatives

• The company will not receive any proceeds from the resale of shares by Mast Hill.
• The market price of the common stock may decline if Mast Hill sells a substantial number of shares.
• Existing stockholders may experience dilution as a result of the issuance of common stock to Mast Hill.
• The company's management has broad discretion over the use of the net proceeds from the sale of shares to Mast Hill, and stockholders may not agree with how the proceeds are used.
• The terms of the Purchase Agreement limit the amount of shares the company may issue to Mast Hill, which may limit the company's ability to utilize the arrangement to enhance its cash resources.

Risks

• It is not possible to predict the actual number of shares Tivic Health will sell to Mast Hill under the Purchase Agreement, or the actual gross proceeds resulting from those sales.
• The terms of the Purchase Agreement limit the amount of shares Tivic Health may issue to Mast Hill, which may limit the company's ability to utilize the arrangement to enhance its cash resources.
• Investors who buy shares at different times will likely pay different prices.
• The issuance of common stock to Mast Hill may cause substantial dilution to Tivic Health's existing stockholders, and the sale of such shares acquired by Mast Hill could cause the price of the company's common stock to decline.
• Tivic Health's management will have broad discretion over the use of the net proceeds from the sale of shares of common stock to Mast Hill pursuant to the Purchase Agreement, if any, and stockholders may not agree with how the company uses the proceeds, and the proceeds may not be invested successfully.
• Stockholders may experience additional dilution as a result of future equity offerings.

Future Outlook

Tivic Health intends to prioritize targets for disease-specific trials planned for 2025 based on clinical research and proprietary market research. The company also plans to validate the manufacturing process for Entolimod and submit a BLA to the FDA. In addition, the company is also preparing to file an IND application and to initiate a phase 2 clinical study for Entolimod for the treatment of neutropenia.

Industry Context

The document mentions that vagus nerve stimulation (VNS) is steadily emerging as a transformative technology in medicine, with the VNS market forecasted to be worth $21 billion in the next five years, growing at a compounded annual growth rate of 10.6%. Implanted stimulators have been approved for, or are nearing approval for, treatment of depression, post-traumatic stress disorder, epilepsy, chronic stroke and rheumatoid arthritis in the U.S. and additional conditions overseas.

Comparison to Industry Standards

• The document mentions Polaris Market Research forecasts that the VNS market will be worth $21 billion in the next five years, growing at a compounded annual growth rate of 10.6%.
• Companies like those behind implanted stimulators for depression, PTSD, epilepsy, chronic stroke, and rheumatoid arthritis are driving practitioner awareness and reimbursement pathways.

Stakeholder Impact

• Existing shareholders may experience dilution of their ownership stake.
• The company's employees may benefit from the potential increase in funding for research and development.
• Customers may benefit from the development of new products and treatments.
• Suppliers may benefit from increased orders and business opportunities.
• Creditors may benefit from the company's improved financial stability.

Next Steps

• The company needs to get the registration statement declared effective by the SEC.
• The company may need to seek stockholder approval to issue additional shares to Mast Hill beyond the Exchange Cap.
• The company will decide on the timing and amount of any sales of common stock to Mast Hill based on market conditions and other factors.
• The company intends to prioritize targets for disease-specific trials planned for 2025 based on clinical research and proprietary market research.
• The company plans to validate the manufacturing process for Entolimod and submit a BLA to the FDA.
• The company is also preparing to file an IND application and to initiate a phase 2 clinical study for Entolimod for the treatment of neutropenia.

Key Dates

Keywords

Tivic Health Systems, Mast Hill Fund, common stock, registration statement, equity purchase agreement, resale, dilution, Entolimod, ClearUP, financing